Astellas, FibroGen (FGEN) Announce Positive Japan Phase 3 Trial for Roxadustat in Chronic Kidney Disease
Tweet Send to a Friend
Astellas Pharma Inc. and FibroGen, Inc. (Nasdaq: FGEN) today announced that the first Phase 3 trial in Japan evaluating roxadustat ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
